AJANTA PHARMA Financial Statement Analysis
|
||
|
The Revenues of AJANTA PHARMA have increased by 15.62% YoY .
The Earnings Per Share (EPS) of AJANTA PHARMA has decreased by -44.04 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
AJANTA PHARMA Last 5 Annual Financial Results
[BOM: 532331|NSE : AJANTPHARM]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹3,341 Cr | ₹2,890 Cr | ₹2,588 Cr | ₹2,055 Cr | ₹2,126 Cr |
| Expenses | ₹2,412 Cr | ₹1,891 Cr | ₹1,905 Cr | ₹1,489 Cr | ₹1,467 Cr |
| Operating Profit (Excl OI) | ₹929 Cr | ₹999 Cr | ₹683 Cr | ₹566 Cr | ₹658 Cr |
| Other Income | ₹116 Cr | ₹26 Cr | ₹92 Cr | ₹21 Cr | ₹24 Cr |
| Interest | ₹10 Cr | ₹8.27 Cr | ₹12 Cr | ₹1.16 Cr | ₹0.41 Cr |
| Depreciation | ₹125 Cr | ₹116 Cr | ₹96 Cr | ₹72 Cr | ₹60 Cr |
| Profit Before Tax | ₹909 Cr | ₹900 Cr | ₹664 Cr | ₹514 Cr | ₹623 Cr |
| Profit After Tax | ₹713 Cr | ₹654 Cr | ₹468 Cr | ₹387 Cr | ₹469 Cr |
| Consolidated Net Profit | ₹713 Cr | ₹654 Cr | ₹468 Cr | ₹387 Cr | ₹469 Cr |
| Earnings Per Share (Rs) | ₹46.70 | ₹83.45 | ₹75.59 | ₹53.60 | ₹44.35 |
| PAT Margin (%) | 15.49 | 20.99 | 22.17 | 18.07 | 18.83 |
| ROE(%) | 17.68 | 22.77 | 23.38 | 19.32 | 18.07 |
| ROCE(%) | 22.57 | 29.37 | 32.20 | 27.44 | 23.84 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 |
Key Financials |
||
| Market Cap | : | ₹ 29,911.3 Cr |
| Revenue (TTM) | : | ₹ 4,208.7 Cr |
| Net Profit(TTM) | : | ₹ 816.2 Cr |
| EPS (TTM) | : | ₹ 64.8 |
| P/E (TTM) | : | 36.6 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| AJANTA PHARMA | -1.6% | 11.3% | 88.7% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.5% | -5.8% | 55.3% |
| CIPLA | -5.9% | -8.4% | 45.7% |
| DR REDDYS LABORATORIES | -6.1% | -4.1% | 19.8% |
| ZYDUS LIFESCIENCES | -3.7% | -1.8% | 84.3% |
| DIVIS LABORATORIES | -4.3% | -0.1% | 15.3% |
| MANKIND PHARMA | -2% | -5.1% | NA |
| TORRENT PHARMACEUTICALS | -4.2% | 0.1% | 51.3% |
| LUPIN | -4.2% | -0.2% | 116.4% |
AJANTA PHARMA Revenues
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | 15.62 % |
| 5 Yr CAGR | 11.97 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹3,341 Cr | 15.62 | |
| Mar2022 | ₹2,890 Cr | 11.66 | |
| Mar2021 | ₹2,588 Cr | 25.91 | |
| Mar2020 | ₹2,055 Cr | -3.31 | |
| Mar2019 | ₹2,126 Cr | - | |
AJANTA PHARMA Operating Profit
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | -6.94 % |
| 5 Yr CAGR | 9.00 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹929 Cr | -6.94 | |
| Mar2022 | ₹999 Cr | 46.13 | |
| Mar2021 | ₹683 Cr | 20.64 | |
| Mar2020 | ₹566 Cr | -13.97 | |
| Mar2019 | ₹658 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -19.53 % |
| 5 Yr CAGR | -2.65 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 27.81% | -19.53 | |
| Mar2022 | 34.56% | 30.91 | |
| Mar2021 | 26.4% | -4.21 | |
| Mar2020 | 27.56% | -11.01 | |
| Mar2019 | 30.97% | - | |
AJANTA PHARMA Profit After Tax
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | 8.99 % |
| 5 Yr CAGR | 11.05 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹713 Cr | 8.99 | |
| Mar2022 | ₹654 Cr | 39.81 | |
| Mar2021 | ₹468 Cr | 20.86 | |
| Mar2020 | ₹387 Cr | -17.43 | |
| Mar2019 | ₹469 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -26.20 % |
| 5 Yr CAGR | -4.76 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 15.49 % | -26.20 | |
| Mar2022 | 20.99 % | -5.32 | |
| Mar2021 | 22.17 % | 22.69 | |
| Mar2020 | 18.07 % | -4.04 | |
| Mar2019 | 18.83 % | - | |
AJANTA PHARMA Earnings Per Share (EPS)
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | -44.04 % |
| 5 Yr CAGR | 1.30 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹47 | -44.04 | |
| Mar2022 | ₹83 | 10.40 | |
| Mar2021 | ₹76 | 41.03 | |
| Mar2020 | ₹54 | 20.86 | |
| Mar2019 | ₹44 | - | |
AJANTA PHARMA Return on Capital Employed (ROCE)
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | -23.15 % |
| 5 Yr CAGR | -1.36 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 22.57% | -23.15 | |
| Mar2022 | 29.37% | -8.79 | |
| Mar2021 | 32.2% | 17.35 | |
| Mar2020 | 27.44% | 15.10 | |
| Mar2019 | 23.84% | - | |
AJANTA PHARMA Share Price vs Sensex
| Current Share Price | : | ₹2,375.8 |
| Current MarketCap | : | ₹ 29,911.3 Cr |
| Updated EOD on | : | May 10,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AJANTA PHARMA | -1.6% |
11.3% |
88.7% |
| SENSEX | -1.6% |
-2.1% |
19% |
AJANTA PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE 250 LARGEMIDCAP | -2.1% | -1.2% | 31.4% |
| S&P BSE LARGE MIDCAP | -2.1% | -1.2% | 31.4% |
| S&P BSE 500 | -2.3% | -1.2% | 33% |
| S&P BSE ALLCAP | -2.4% | -1.2% | 34.7% |
| S&P BSE HEALTHCARE | -2.5% | -2.4% | 50% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDCAP150 QUALITY 50 | -1% | 1.6% | 32.7% |
| NIFTY LARGE MIDCAP 250 | -2.3% | -0.8% | 39.9% |
| NIFTY 500 | -2.3% | -1.2% | 34% |
| NIFTY MIDCAP150 | -2.6% | -0.3% | 52.7% |
| NIFTY500 MULTICAP 50:25:25 | -2.8% | -1% | 41.4% |
You may also like the below Video Courses
FAQ about AJANTA PHARMA Financials
How the annual revenues of AJANTA PHARMA have changed ?
The Revenues of AJANTA PHARMA have increased by 15.62% YoY .
How the Earnings per Share (EPS) of AJANTA PHARMA have changed?
The Earnings Per Share (EPS) of AJANTA PHARMA has decreased by -44.04 % YoY .
Check out Intrinsic Value of Peers of AJANTA PHARMA
Compare Stock Analytics of Peers of AJANTA PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
